BCIQ Profiles

Company Profile Report

IMP321: Ph I TACTI-mel ongoing

An independent DSMB recommended continuation of the open-label, Australian Phase I TACTI-mel trial evaluating

Read the full 148 word article

How to gain access

Continue reading with a
two-week free trial.